Where is Genbio AI located?

Genbio AI is headquartered in Palo Alto, United States.

Who is the current CEO of Genbio AI?

Fred Hu of Genbio AI. They have also founded 1 company.

How many employees does Genbio AI have?

As of Jan 31, 2026, the latest employee count at Genbio AI is 47.

Is Genbio AI a funded company?

Genbio AI is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does Genbio AI rank among its competitors?

Genbio AI ranks 31st amongst 139 active competitors, of which 61 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was XtalPi, which secured $268M in Sep, 2025.

Who are the top competitors of Genbio AI?

Genbio AI's top competitors include Recursion Pharmaceuticals, Benevolent and XtalPi. Among them, XtalPi secured the most recent funding round in September, 2025.

Genbio AI - 2026 Company Profile, Team & Competitors

Company Details

Developer of AI-driven models for biological research and drug discovery. These models simulate biological systems at various scales, from molecules to organisms, accelerating drug development and enhancing understanding of diseases. Applications include simulating treatments, predicting effects on complex systems, and enabling personalized medicine through digital patient simulations. The models provide actionable insights for advancements in healthcare, green technologies, and consumer innovation.

Key Metrics

Founded Year

2024

Location

Palo Alto, United States

Stage

Unfunded

Ranked

31^st among 139 active competitors

Employee Count

47 as on Jan 31, 2026

Similar Companies

Innovaccer & 2428 more

View Genbio AI's full profile

Genbio AI has not raised any funding rounds yet.

The founders of Genbio AI is Fred Hu. Fred Hu is the CEO of Genbio AI.

Here are the details of Genbio AI's key team members:

Fred Hu: Co-Founder & CEO of Genbio AI.
Contact Info: 1 email address

View details of Genbio AI's Founder profiles and Board Members

Genbio AI's employee count trend

Genbio AI has 47 employees as of Jan 26. Here is Genbio AI's employee count trend over the years:

Uncover Genbio AI's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Genbio AI include Recursion Pharmaceuticals, Benevolent and XtalPi. Here is the list of Top 10 competitors of Genbio AI, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Recursion Pharmaceuticals 2013, New York (United States), Public	AI-enabled drug discovery and development platform for novel therapeutics	$452M	Baillie Gifford, DCVC & 46 others	72/100
2nd	Benevolent 2013, London (United Kingdom), Public	AI powered platform for drug discovery and development	$282M	Woodford Investment Management, Temasek & 16 others	70/100
3rd	XtalPi 2014, Cambridge (United States), Public	AI-based drug research and development company	$785M	Orbimed, SoftBank Vision Fund & 25 others	67/100
4th	Schrodinger 1990, New York City (United States), Acquired	Provider of a web-based simulation and modelling tool	$162M	Gates Foundation, WuXi AppTec & 16 others	66/100
5th	Healx 2014, Cambridge (United Kingdom), Series C	AI-powered drug discovery platform to treat rare diseases	$115M	Atomico, Balderton Capital & 17 others	64/100
6th	Xaira 2023, San Francisco (United States), Series D	AI-enabled platform for drug discovery and development	$1B	Arch Venture Partners, Foresite Labs & 11 others	63/100
7th	Valo Health 2019, Boston (United States), Series B	AI-powered platform for drug discovery and development	$450M	PSP Investments, Koch Disruptive Technologies ... & 7 others	62/100
8th	METiS Therapeutics 2017, Cambridge (United States), Series B	Provider of an AI-assisted platform for drug discovery and development	$252M	Sequoia Capital China, Luminous Ventures ... & 13 others	62/100
9th	In Silico 2014, Cambridge (United States), Public	AI-enabled bioinformatics platform for drug discovery and biomarker development	$510M	Qiming Venture Partners, Warburg Pincus & 36 others	62/100
10th	Aqemia 2019, Paris (France), Series A	Provider of an AI and quantum physics to discover therapeutic molecules	$103M	Eurazeo, Bpifrance & 4 others	62/100
31st	Genbio AI 2024, Palo Alto (United States), Unfunded	Developer of AI-driven models for biological research and drug discovery	-	-	49/100